Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
April 02, 2024 07:00 ET
|
Avalo Therapeutics
Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo’s recent acquisition of...
Avalo Reports 2023 Financial Results and Provides Business Updates
March 29, 2024 16:01 ET
|
Avalo Therapeutics
Acquired AVTX-009, Phase-2 ready anti-IL-1β mAb, in March 2024Increased cash position with private placement financing in March 2024 providing up to $185 million, including initial upfront investment...
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
March 27, 2024 16:01 ET
|
Avalo Therapeutics
Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026Executed private...
Avalo Therapeutics Announces 1-for-240 Reverse Stock Split
December 27, 2023 07:00 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced a 1-for-240 reverse stock split of the Company’s common stock, par value...
Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split
December 07, 2023 07:00 ET
|
Avalo Therapeutics
Annual Meeting has been adjourned until December 20, 2023Most stockholders can vote via proxyvote.com or by calling 1-800-690-6903. If you have any questions about how to vote, please call...
Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 09, 2023 07:00 ET
|
Avalo Therapeutics
Successfully eliminated $35 million debt paving the way for future growth and innovationDivested AVTX-800 series for potential milestone payments of $45 million, fully focusing the pipeline on Avalo’s...
Avalo Completes Divestiture of AVTX-800 Series
October 31, 2023 07:00 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it has completed the divestiture of its rights, title and interest in,...
Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation
September 26, 2023 07:00 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- In a major achievement, Avalo Therapeutics (Nasdaq: AVTX) proudly announces the payoff of the remainder of its $35 million debt owed...
Avalo Enters into Agreement to Divest AVTX-800 Series
September 12, 2023 07:00 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md. , Sept. 12, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it entered into a purchase agreement (the Purchase Agreement) with AUG...
Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 07:00 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board,...